Evans syndrome revisited
Abstract
Evans syndrome (ES) is a rare acquired autoimmune disease defined by the presence of at least two of the three autoimmune cytopenias: immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and autoimmune neutropenia. At an incidence of approximately 10 to 30 times lower than AIHA and ITP, respectively, ES has been historically overlooked and our understanding of the pathogenesis, clinical characteristics, and optimal management strategies for ES lags behind. Observational studies suggest that although initial response rates to standard therapies are similar, long-term outcomes and mortality in ES are worse than in AIHA and ITP. A panoply of novel therapies is now available or in development for ITP and to a lesser extent, AIHA. In this review, we revisit our understanding of the pathophysiology and clinical features of adult ES and discuss the potential novel therapeutics that might hold promise for patients with Evans syndrome.
Read the paper
Related studies
- Current state and future directions for deep learning based automatic seismic fault interpretation: A systematic review
- Physics of Partially Saturated Porous Media: Residual Saturation and Seismic-Wave Propagation
- Modern Imaging Using Seismic Reflection Data
- Effects of marine seismic surveys on free-ranging fauna: a systematic literature review
- A review of the recent seismic activity in the southern part of egypt (upper egypt)
- A review of research on mechanism of seismic attenuation and energy compensation
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.